Natural History of β-Cell Autoimmunity in Young Children with Increased Genetic Susceptibility to Type 1 Diabetes Recruited from the General Population
The aim of this study was to evaluate the frequency and predictive value of diabetes-associated autoantibodies, such as islet cell antibodies (ICA) and autoantibodies to insulin (IAA), GAD65 (GADA), and the IA-2 molecule (IA-2A) in genetically susceptible children from the general population during...
Saved in:
Published in | The journal of clinical endocrinology and metabolism Vol. 87; no. 10; pp. 4572 - 4579 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Endocrine Society
01.10.2002
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The aim of this study was to evaluate the frequency and predictive value of diabetes-associated autoantibodies, such as islet cell antibodies (ICA) and autoantibodies to insulin (IAA), GAD65 (GADA), and the IA-2 molecule (IA-2A) in genetically susceptible children from the general population during the first 2 yr of life. Of 12,170 newborn infants, 1,005 with increased genetic risk of type 1 diabetes (high risk, human leukocyte antigen DQB1*02/*0302; moderate risk, DQB1*0302/x, where x = other than *02, *0301, or *0602) were monitored for ICA, IAA, GADA, and IA-2A at 3- to 6-month intervals from birth up to a minimum age of 2 yr. In addition, all 15 genetically susceptible children from the general population who had participated in regular immunological follow-up and developed clinical type 1 diabetes by the end of April 2000 were analyzed for the development of autoantibodies. Among 1,005 children, 63 (6.3%) tested positive for at least one autoantibody, 31 for ICA (3.1%), 48 for IAA (4.8%), 23 for GADA (2.3%), and 13 for IA-2A (1.3%) at least once by the age of 2 yr. Both ICA and IAA identified 95% [95% confidence interval (CI), 77.2–99.9%] of those who tested persistently positive for multiple (≥2) antibodies at the age of 2 yr, GADA identified 86% (CI, 65.1–97.1%), and IA-2A identified 55% (CI, 32.2–75.6%). Close to half of the antibody-positive children (29 of 63) reverted back to antibody negativity. Autoantibodies disappeared more often among those who tested positive for IAA than among those who tested positive for other autoantibodies (P ≤ 0.021). Among the 15 children who developed type 1 diabetes, the disease sensitivity of ICA was 80% (CI, 51.9–95.7%), that of IAA was 93% (CI, 68.0–99.8%), that of GADA was 60% (CI, 32.3–83.7%), and that of IA-2A was 40% (CI, 16.3–67.7%). These results suggest that IAA are characterized by high sensitivity, early appearance, and high frequency of transient antibody positivity, whereas ICA detected with a thoroughly standardized assay appear to be more specific for the screening of β-cell autoimmunity in young children with increased genetic susceptibility to type 1 diabetes in the Finnish population, which has the highest incidence of type 1 diabetes in the world. |
---|---|
AbstractList | The aim of this study was to evaluate the frequency and predictive value of diabetes-associated autoantibodies, such as islet cell antibodies (ICA) and autoantibodies to insulin (IAA), GAD65 (GADA), and the IA-2 molecule (IA-2A) in genetically susceptible children from the general population during the first 2 yr of life. Of 12,170 newborn infants, 1,005 with increased genetic risk of type 1 diabetes (high risk, human leukocyte antigen DQB1*02/*0302; moderate risk, DQB1*0302/x, where x = other than *02, *0301, or *0602) were monitored for ICA, IAA, GADA, and IA-2A at 3- to 6-month intervals from birth up to a minimum age of 2 yr. In addition, all 15 genetically susceptible children from the general population who had participated in regular immunological follow-up and developed clinical type 1 diabetes by the end of April 2000 were analyzed for the development of autoantibodies. Among 1,005 children, 63 (6.3%) tested positive for at least one autoantibody, 31 for ICA (3.1%), 48 for IAA (4.8%), 23 for GADA (2.3%), and 13 for IA-2A (1.3%) at least once by the age of 2 yr. Both ICA and IAA identified 95% [95% confidence interval (CI), 77.2-99.9%] of those who tested persistently positive for multiple (> or = 2) antibodies at the age of 2 yr, GADA identified 86% (CI, 65.1-97.1%), and IA-2A identified 55% (CI, 32.2-75.6%). Close to half of the antibody-positive children (29 of 63) reverted back to antibody negativity. Autoantibodies disappeared more often among those who tested positive for IAA than among those who tested positive for other autoantibodies (P < or = 0.021). Among the 15 children who developed type 1 diabetes, the disease sensitivity of ICA was 80% (CI, 51.9-95.7%), that of IAA was 93% (CI, 68.0-99.8%), that of GADA was 60% (CI, 32.3-83.7%), and that of IA-2A was 40% (CI, 16.3-67.7%). These results suggest that IAA are characterized by high sensitivity, early appearance, and high frequency of transient antibody positivity, whereas ICA detected with a thoroughly standardized assay appear to be more specific for the screening of beta-cell autoimmunity in young children with increased genetic susceptibility to type 1 diabetes in the Finnish population, which has the highest incidence of type 1 diabetes in the world. The aim of this study was to evaluate the frequency and predictive value of diabetes-associated autoantibodies, such as islet cell antibodies (ICA) and autoantibodies to insulin (IAA), GAD65 (GADA), and the IA-2 molecule (IA-2A) in genetically susceptible children from the general population during the first 2 yr of life. Of 12,170 newborn infants, 1,005 with increased genetic risk of type 1 diabetes (high risk, human leukocyte antigen DQB1*02/*0302; moderate risk, DQB1*0302/x, where x = other than *02, *0301, or *0602) were monitored for ICA, IAA, GADA, and IA-2A at 3- to 6-month intervals from birth up to a minimum age of 2 yr. In addition, all 15 genetically susceptible children from the general population who had participated in regular immunological follow-up and developed clinical type 1 diabetes by the end of April 2000 were analyzed for the development of autoantibodies. Among 1,005 children, 63 (6.3%) tested positive for at least one autoantibody, 31 for ICA (3.1%), 48 for IAA (4.8%), 23 for GADA (2.3%), and 13 for IA-2A (1.3%) at least once by the age of 2 yr. Both ICA and IAA identified 95% [95% confidence interval (CI), 77.2-99.9%] of those who tested persistently positive for multiple (> or = 2) antibodies at the age of 2 yr, GADA identified 86% (CI, 65.1-97.1%), and IA-2A identified 55% (CI, 32.2-75.6%). Close to half of the antibody-positive children (29 of 63) reverted back to antibody negativity. Autoantibodies disappeared more often among those who tested positive for IAA than among those who tested positive for other autoantibodies (P < or = 0.021). Among the 15 children who developed type 1 diabetes, the disease sensitivity of ICA was 80% (CI, 51.9-95.7%), that of IAA was 93% (CI, 68.0-99.8%), that of GADA was 60% (CI, 32.3-83.7%), and that of IA-2A was 40% (CI, 16.3-67.7%). These results suggest that IAA are characterized by high sensitivity, early appearance, and high frequency of transient antibody positivity, whereas ICA detected with a thoroughly standardized assay appear to be more specific for the screening of beta-cell autoimmunity in young children with increased genetic susceptibility to type 1 diabetes in the Finnish population, which has the highest incidence of type 1 diabetes in the world. The aim of this study was to evaluate the frequency and predictive value of diabetes-associated autoantibodies, such as islet cell antibodies (ICA) and autoantibodies to insulin (IAA), GAD65 (GADA), and the IA-2 molecule (IA-2A) in genetically susceptible children from the general population during the first 2 yr of life. Of 12,170 newborn infants, 1,005 with increased genetic risk of type 1 diabetes (high risk, human leukocyte antigen DQB1*02/*0302; moderate risk, DQB1*0302/x, where x = other than *02, *0301, or *0602) were monitored for ICA, IAA, GADA, and IA-2A at 3- to 6-month intervals from birth up to a minimum age of 2 yr. In addition, all 15 genetically susceptible children from the general population who had participated in regular immunological follow-up and developed clinical type 1 diabetes by the end of April 2000 were analyzed for the development of autoantibodies. Among 1,005 children, 63 (6.3%) tested positive for at least one autoantibody, 31 for ICA (3.1%), 48 for IAA (4.8%), 23 for GADA (2.3%), and 13 for IA-2A (1.3%) at least once by the age of 2 yr. Both ICA and IAA identified 95% [95% confidence interval (CI), 77.2–99.9%] of those who tested persistently positive for multiple (≥2) antibodies at the age of 2 yr, GADA identified 86% (CI, 65.1–97.1%), and IA-2A identified 55% (CI, 32.2–75.6%). Close to half of the antibody-positive children (29 of 63) reverted back to antibody negativity. Autoantibodies disappeared more often among those who tested positive for IAA than among those who tested positive for other autoantibodies (P ≤ 0.021). Among the 15 children who developed type 1 diabetes, the disease sensitivity of ICA was 80% (CI, 51.9–95.7%), that of IAA was 93% (CI, 68.0–99.8%), that of GADA was 60% (CI, 32.3–83.7%), and that of IA-2A was 40% (CI, 16.3–67.7%). These results suggest that IAA are characterized by high sensitivity, early appearance, and high frequency of transient antibody positivity, whereas ICA detected with a thoroughly standardized assay appear to be more specific for the screening of β-cell autoimmunity in young children with increased genetic susceptibility to type 1 diabetes in the Finnish population, which has the highest incidence of type 1 diabetes in the world. |
Author | Kimpimäki, T Savola, K Simell, O Kulmala, P Ilonen, J Korhonen, S Knip, M Simell, T Kupila, A |
Author_xml | – sequence: 1 givenname: T surname: Kimpimäki fullname: Kimpimäki, T – sequence: 2 givenname: P surname: Kulmala fullname: Kulmala, P – sequence: 3 givenname: K surname: Savola fullname: Savola, K – sequence: 4 givenname: A surname: Kupila fullname: Kupila, A – sequence: 5 givenname: S surname: Korhonen fullname: Korhonen, S – sequence: 6 givenname: T surname: Simell fullname: Simell, T – sequence: 7 givenname: J surname: Ilonen fullname: Ilonen, J – sequence: 8 givenname: O surname: Simell fullname: Simell, O – sequence: 9 givenname: M surname: Knip fullname: Knip, M |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/12364437$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kc9uEzEQxq2qqE0L1x4rn7htsHedePdYpdBWqgBBkeBkeb3jxpHX3vqPUN6E5-iD8Ex1mkicuMwc5vd9mpnvDB077wChC0rmtKbkw0bNa0LqipRK2yM0ox1bVJx2_BjNyoBWHa9_nqKzGDeFYGzRnKBTWjdLxho-Q38-y5SDtPjWxOTDFnuN_z5XK7AWX-XkzThmZ9IWG4d_-ewe8Wpt7BDA4d8mrfGdUwFkhAHfgINkFP6eo4Ipmd7YnS55_LCdAFN8bWQPCSL-Bipkk4pGBz_itIZX8W6Lr37KVibj3Vv0Rksb4d2hn6Mfnz4-rG6r-y83d6ur-0o1nKcKOhgaNTDdyCVlvew0lL_0Ui1h0WrNlOypXPYtBQK8DAc-0JZQyXtS2FY35-j93ncK_ilDTGI05QBrpQOfo-A1ZW3D2wLO96AKPsYAWkzBjDJsBSVil4XYKLHLQuyzKILLg3PuRxj-4YfnF2CxB8ANXgXjYAoQo9j4HFy5-X_GL2T2nJc |
CitedBy_id | crossref_primary_10_1097_MPG_0b013e31805fc256 crossref_primary_10_1111_j_1753_0407_2010_00102_x crossref_primary_10_1111_j_1365_2249_2011_04324_x crossref_primary_10_1210_clinem_dgaa624 crossref_primary_10_1007_s00125_017_4258_7 crossref_primary_10_6065_apem_2014_19_2_76 crossref_primary_10_1111_nyas_12021 crossref_primary_10_2337_dc19_1731 crossref_primary_10_3389_fimmu_2024_1345494 crossref_primary_10_1007_s11892_005_0035_y crossref_primary_10_2337_diacare_29_03_06_dc05_0774 crossref_primary_10_1017_S0007114510003338 crossref_primary_10_2337_dc16_0181 crossref_primary_10_1111_j_1399_5448_2006_00225_x crossref_primary_10_1111_j_1399_5448_2007_00349_x crossref_primary_10_2337_dc10_2324 crossref_primary_10_1016_j_clim_2010_09_002 crossref_primary_10_1084_jem_20081800 crossref_primary_10_1016_j_jaut_2009_04_003 crossref_primary_10_1016_S1696_2818_03_71581_9 crossref_primary_10_1210_jc_2019_01069 crossref_primary_10_1016_j_jfma_2016_07_005 crossref_primary_10_1038_sdata_2018_250 crossref_primary_10_1111_pedi_12812 crossref_primary_10_1007_s00251_017_0999_1 crossref_primary_10_1016_j_autrev_2009_02_019 crossref_primary_10_4049_jimmunol_1000820 crossref_primary_10_1007_s00125_006_0225_4 crossref_primary_10_1002_dmrr_998 crossref_primary_10_1007_s00125_007_0617_0 crossref_primary_10_3390_ijms22147493 crossref_primary_10_1210_jc_2019_00421 crossref_primary_10_1007_s00125_005_1844_x crossref_primary_10_3389_fendo_2022_933965 crossref_primary_10_1007_s00125_008_0945_8 crossref_primary_10_2337_dc06_0711 crossref_primary_10_3345_kjp_2010_53_3_414 crossref_primary_10_1515_CCLM_2008_138 crossref_primary_10_1111_pedi_12386 crossref_primary_10_1007_s11892_018_1066_5 crossref_primary_10_1016_j_retram_2018_01_003 crossref_primary_10_1002_dmrr_506 crossref_primary_10_1007_s00125_010_1713_0 crossref_primary_10_1016_j_clim_2006_09_004 crossref_primary_10_1136_bmjopen_2021_052449 crossref_primary_10_1002_dmrr_1294 crossref_primary_10_2337_diabetes_54_suppl_2_S25 crossref_primary_10_1007_s00281_017_0665_6 crossref_primary_10_1016_S0929_6646_09_60417_4 crossref_primary_10_1371_journal_pone_0033574 crossref_primary_10_1161_CIRCULATIONAHA_106_641472 crossref_primary_10_1111_j_1399_543X_2005_00129_x crossref_primary_10_1111_j_1399_5448_2007_00256_x crossref_primary_10_2337_diacare_27_3_676 crossref_primary_10_31146_1682_8658_ecg_202_6_27_35 crossref_primary_10_4239_wjd_v11_i11_527 crossref_primary_10_1002_bmc_3050 crossref_primary_10_2337_diabetes_53_2_384 crossref_primary_10_1007_s00125_017_4256_9 crossref_primary_10_1111_j_1399_5448_2009_00574_x crossref_primary_10_1007_s00125_023_06075_3 crossref_primary_10_1080_07435800802080328 crossref_primary_10_1210_endrev_bnab013 crossref_primary_10_1007_s00592_011_0364_z crossref_primary_10_1016_j_jaut_2004_03_008 crossref_primary_10_2337_diacare_27_12_2784 crossref_primary_10_1016_j_beem_2004_11_009 crossref_primary_10_1111_cei_13391 crossref_primary_10_1007_s00125_024_06205_5 crossref_primary_10_1373_clinchem_2010_148205 crossref_primary_10_2337_diabetes_54_suppl_2_S52 crossref_primary_10_1016_j_clim_2008_11_004 crossref_primary_10_1172_JCI200421307 crossref_primary_10_1210_jc_2004_1371 crossref_primary_10_3109_10408361003787171 crossref_primary_10_3945_ajcn_110_000646 crossref_primary_10_1007_s00125_009_1438_0 crossref_primary_10_1530_EJE_07_0853 crossref_primary_10_1002_dmrr_3132 crossref_primary_10_1515_jpem_2019_0103 crossref_primary_10_1016_j_jaut_2008_01_001 crossref_primary_10_1196_annals_1375_055 crossref_primary_10_1530_REP_13_0614 crossref_primary_10_1016_j_clim_2012_09_010 crossref_primary_10_1136_bmjopen_2018_028578 crossref_primary_10_1371_journal_pone_0051909 crossref_primary_10_1016_S2213_8587_19_30412_7 crossref_primary_10_2337_db13_0300 crossref_primary_10_1111_j_1399_5448_2010_00697_x crossref_primary_10_1007_s00125_005_1864_6 crossref_primary_10_1016_j_diabres_2021_108798 crossref_primary_10_1007_s11892_008_0017_y crossref_primary_10_1186_1479_5876_9_203 crossref_primary_10_1016_j_clim_2007_03_545 crossref_primary_10_2337_dc22_1960 crossref_primary_10_1016_j_diabres_2005_10_022 crossref_primary_10_1007_s00125_014_3294_9 crossref_primary_10_1002_dmrr_2864 crossref_primary_10_1586_1744666X_5_1_55 crossref_primary_10_1016_j_cll_2004_01_012 crossref_primary_10_1038_gene_2015_43 crossref_primary_10_1007_s11428_018_0341_z |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
DOI | 10.1210/jc.2002-020018 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1945-7197 |
EndPage | 4579 |
ExternalDocumentID | 10_1210_jc_2002_020018 12364437 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | - 02 08R 0R 1TH 29K 2WC 34G 39C 3O- 3V. 4.4 48X 53G 55 5GY 5RS 5YH 7X7 88E 8F7 8FI 8FJ AABJS AABMN AAIMJ AAJQQ AAPQZ AAQQT AAUQX AAWTL AAYJJ ABFLS ABOCM ABPMR ABPPZ ABSAR ABUWG ACGFS ACIMA ACPRK ACUTJ ADBBV ADBIT ADEIU ADGZP ADHKW ADRTK AELNO AELWJ AEMDU AENEX AENZO AETBJ AEWNT AFCHL AFFNX AFKRA AFRAH AFXEN AGINJ AGKRT AGVJH AHMBA AIKOY AIMBJ ALMA_UNASSIGNED_HOLDINGS APIBT AQKUS ARIXL ASMCH ASPBG AVWKF AYOIW AZFZN AZQFJ BAWUL BAYMD BBAFP BCRHZ BENPR BEYMZ BGYMP BHONS BPHCQ BSWAC BTRTY BVXVI C45 CDBKE CS3 D-I DAKXR DIK DPPUQ E3Z EBS EIHJH EJD ENERS F5P FEDTE FH7 FHSFR FOTVD FQBLK FYUFA G8K GAUVT GJ GJXCC GX1 H1 H13 HVGLF HZ H~9 IAO IHR INH J5H KBUDW KOP KQ8 KSN L7B M1P M5 MBLQV MHKGH N9A NLBLG NOYVH NVLIB O0- O9- OBH OCB ODMLO OGEVE OK1 OVD P2P PQEST PQQKQ PQUKI PRINS PROAC PSQYO REU ROX ROZ TCN TJX TLC TMA TWZ VH1 WOQ X X52 X7M XZ ZA5 ZGI ZXP ZY1 --- -~X .55 .GJ .XZ 08P 0R~ 18M 354 AABZA AACZT AAKAS AAPGJ AAPXW AARHZ AAUAY AAVAP AAWDT ABBLC ABJNI ABLJU ABMNT ABNHQ ABPQP ABPTD ABQNK ABWST ABXVV ACFRR ACGFO ACYHN ACZBC ADGKP ADQBN ADVEK ADZCM AERZD AFFZL AFGWE AFOFC AFXAL AFYAG AGMDO AGQXC AGUTN AI. AJEEA APJGH AQDSO ATGXG AVNTJ CGR CUY CVF ECM EIF EMOBN FECEO FLUFQ FOEOM HZ~ ITC KSI M5~ MJL N4W NOMLY NPM OAUYM OFXIZ OHH OJZSN OPAEJ OVIDX P6G TEORI TR2 VVN W8F WHG YBU YFH YHG YOC YSK ~02 ~H1 AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-c377t-e9ed3cd4f3a614ba9fe121bac6e58ff4cab1a6b81e0e79fed7d1801a7b0a9f8f3 |
ISSN | 0021-972X |
IngestDate | Thu Aug 15 23:03:17 EDT 2024 Thu Sep 26 19:14:02 EDT 2024 Sat Sep 28 07:48:32 EDT 2024 Tue Jan 05 21:44:35 EST 2021 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 10 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c377t-e9ed3cd4f3a614ba9fe121bac6e58ff4cab1a6b81e0e79fed7d1801a7b0a9f8f3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://academic.oup.com/jcem/article-pdf/87/10/4572/9155409/jcem4572.pdf |
PMID | 12364437 |
PQID | 72148378 |
PQPubID | 23479 |
PageCount | 8 |
ParticipantIDs | proquest_miscellaneous_72148378 crossref_primary_10_1210_jc_2002_020018 pubmed_primary_12364437 endocrinepress_journals_10_1210_jc_2002_020018 |
PublicationCentury | 2000 |
PublicationDate | 2002-10 2002-Oct 2002-10-00 20021001 |
PublicationDateYYYYMMDD | 2002-10-01 |
PublicationDate_xml | – month: 10 year: 2002 text: 2002-10 |
PublicationDecade | 2000 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | The journal of clinical endocrinology and metabolism |
PublicationTitleAlternate | J Clin Endocrinol Metab |
PublicationYear | 2002 |
Publisher | Endocrine Society |
Publisher_xml | – name: Endocrine Society |
SSID | ssj0014453 |
Score | 2.1495066 |
Snippet | The aim of this study was to evaluate the frequency and predictive value of diabetes-associated autoantibodies, such as islet cell antibodies (ICA) and... |
SourceID | proquest crossref pubmed endocrinepress |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 4572 |
SubjectTerms | Aging Autoantibodies - blood Autoimmunity - genetics Diabetes Mellitus, Type 1 - genetics Diabetes Mellitus, Type 1 - immunology Genetic Predisposition to Disease Glutamate Decarboxylase - immunology Humans Infant Insulin Antibodies - blood Islets of Langerhans - immunology Isoenzymes - immunology |
Title | Natural History of β-Cell Autoimmunity in Young Children with Increased Genetic Susceptibility to Type 1 Diabetes Recruited from the General Population |
URI | http://dx.doi.org/10.1210/jc.2002-020018 https://www.ncbi.nlm.nih.gov/pubmed/12364437 https://search.proquest.com/docview/72148378 |
Volume | 87 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3JjtNAEG2FQUIcQOyEtQ6MOESOvLTT8TGEgRHSjEaajJSb1bbbUlBiR8S-8CV8Bx_CP_AnVHW3l6CMNHCxko63uF7X4q56xdg7GSTTIPAxTOWZdMhhxznHEyeTecbdPEgnmuz57HxyesW_LMPlYPC7l7VUV8k4_X6wruR_pIpjKFeqkv0HybYnxQH8jPLFLUoYtzeS8bk0rBmG60OvlR_PT44_-M6cXsnN6qpc6fqPSlf36ZltyIyb8m3SD5SWjm4nEVATe-tlvdOpLjprVvumFKuOvNHH5jUtuZq1dlXb4hTLXj26aPuB9b1ewmKPoqKtxlRFVqLWKjoeqI2qEJXrhtdQJwdstquNXs_npsX2YtytP603cq3d34t28FKixjWFbr0dtyszNhvvvefw24y5ru7AcyKhm6-j5TLqOuKhIzyT4dvoc2vALW7dnnbmoWkTZC09fo0OWhEMg8mKaIZL33Ep7Wza2csmR-AvM9omN1JYhWeIv6bU49OPzfG32G1fRCFlnX5etllIGM5aolT75yyvKBVW7V9_z2-618jHZEtfHx1pL2nxgN234Q3MDFYfsoEqHrE7ZzaB4zH7YSELFrJQ5vDrp4Yr9OEKqwI0XKGBKxBcoYUrWLjCPlyhKoHgCh40cIUWrkBwBYQrWLhCB9cn7OrTyWJ-6tjmIE4aCFE5KlJZkGY8DyR6mImMcoVPLZHpRIXTPOepTDw5SaaecpXAHzOReeiNSZG4uO80D56yo6Is1HMGrsSoWXA5ibKAE5E1wioLvBTVmJ-GUTRk75tHH28NB0x8WMhDNt6XTGwn1-7aA942kotRr9NinSxUWe9i4Xu62cOQPTMC7S5NPR94IF7c-LZesrvdjHrFjqpvtXqNvnSVvNFo_APaH8tY |
link.rule.ids | 315,786,790,27955,27956 |
linkProvider | Geneva Foundation for Medical Education and Research |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Natural+History+of+%CE%B2-Cell+Autoimmunity+in+Young+Children+with+Increased+Genetic+Susceptibility+to+Type+1+Diabetes+Recruited+from+the+General+Population&rft.jtitle=The+journal+of+clinical+endocrinology+and+metabolism&rft.au=Kimpim%C3%A4ki%2C+T.&rft.au=Kulmala%2C+P.&rft.au=Savola%2C+K.&rft.au=Kupila%2C+A.&rft.date=2002-10-01&rft.issn=0021-972X&rft.eissn=1945-7197&rft.volume=87&rft.issue=10&rft.spage=4572&rft.epage=4579&rft_id=info:doi/10.1210%2Fjc.2002-020018&rft.externalDBID=n%2Fa&rft.externalDocID=10_1210_jc_2002_020018 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0021-972X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0021-972X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0021-972X&client=summon |